DOMAGROZUMAB

Domagrozumab is an antibody targeting myostatin to enhance muscle growth, studied in muscular dystrophy. Side effects include injection-site reactions and potential immune responses. Only GMP materials will be supplied, logistics all according to GDP.

SKU: 964b5bdcb1b3 Category: Tag:

Product Description


Mechanism of Action

Domagrozumab is a humanized monoclonal antibody that binds myostatin (GDF8), a TGF family cytokine that negatively regulates muscle growth. By neutralizing myostatin, domagrozumab enhances muscle fibre size, increases satellitecell activity and promotes hypertrophy. It modulates SMAD2/3 signalling and counteracts catabolic gene expression.

Benefits and Advantages

Used in muscleregeneration research, Duchenne muscular dystrophy modelling, myostatinpathway inhibition assays, SMADsignalling studies and anabolictherapeutic development.

Side Effects and Risks

Risks include injectionsite reactions, immune responses, muscle enzyme elevation and unknown longterm metabolic effects. Handle with monoclonalantibody precautions.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

Protein

Molecular Weight

150000.0 g/mol

CAS Number

1393551-88-2

Storage Condition

Store in a cool, dry place; protect from light

Solubility

Soluble in water

Purity

Purity information is available upon request (COA).

IUPAC/Chemical Name

Monoclonal antibody

InChl Key

Unavailable

InChl Code

Unavailable

References

PubChem; ChemBL; FDA;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download